60,511 Shares in Adicet Bio, Inc. $ACET Acquired by Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals Inc. purchased a new position in Adicet Bio, Inc. (NASDAQ:ACET) during the second quarter, Holdings Channel reports. The fund purchased 60,511 shares of the company’s stock, valued at approximately $522,819,000. Adicet Bio accounts for 0.3% of Regeneron Pharmaceuticals Inc.’s holdings, making the stock its 3rd largest holding.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Goldman Sachs Group Inc. boosted its stake in shares of Adicet Bio by 1.7% during the first quarter. Goldman Sachs Group Inc. now owns 3,816,556 shares of the company’s stock valued at $2,882,000 after purchasing an additional 63,691 shares during the period. Two Sigma Investments LP increased its stake in shares of Adicet Bio by 66.6% in the third quarter. Two Sigma Investments LP now owns 854,568 shares of the company’s stock worth $692,000 after buying an additional 341,761 shares during the period. Franklin Resources Inc. purchased a new position in shares of Adicet Bio in the fourth quarter worth $5,276,000. Citadel Advisors LLC raised its holdings in Adicet Bio by 19.8% during the 3rd quarter. Citadel Advisors LLC now owns 583,948 shares of the company’s stock valued at $473,000 after buying an additional 96,342 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. bought a new stake in Adicet Bio during the 4th quarter valued at $2,310,000. Institutional investors own 83.89% of the company’s stock.

Adicet Bio Stock Performance

NASDAQ:ACET opened at $9.11 on Wednesday. The stock has a market cap of $85.27 million, a P/E ratio of -0.80 and a beta of 1.60. The firm’s fifty day simple moving average is $8.42 and its 200 day simple moving average is $7.82. Adicet Bio, Inc. has a twelve month low of $6.01 and a twelve month high of $17.44. The company has a quick ratio of 6.71, a current ratio of 6.71 and a debt-to-equity ratio of 0.01.

Adicet Bio (NASDAQ:ACET) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.99) EPS for the quarter, missing the consensus estimate of ($1.69) by ($0.30). As a group, research analysts predict that Adicet Bio, Inc. will post -6.76 EPS for the current year.

Wall Street Analysts Forecast Growth

ACET has been the topic of a number of recent analyst reports. Guggenheim reissued a “buy” rating and issued a $90.00 price target (down from $100.00) on shares of Adicet Bio in a report on Thursday, August 6th. Weiss Ratings raised shares of Adicet Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, May 26th. Wall Street Zen upgraded shares of Adicet Bio from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Finally, Jefferies Financial Group began coverage on shares of Adicet Bio in a report on Tuesday, May 5th. They set a “buy” rating and a $19.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Adicet Bio presently has an average rating of “Moderate Buy” and an average target price of $46.80.

About Adicet Bio

Adicet Bio, Inc (NASDAQ: ACET) is a clinical‐stage biotechnology company specializing in the development of off‐the‐shelf, allogeneic gamma delta (γδ) T cell therapies for oncology and autoimmune disorders. The company’s proprietary platform enables the genetic engineering of γδ T cells with chimeric antigen receptors (CARs) and other molecular modifications to enhance tumor targeting, expansion, and persistence. By leveraging the innate tumor-recognition properties of γδ T cells, Adicet seeks to overcome the manufacturing and safety challenges associated with autologous cell therapies.

Adicet’s lead product candidate, ADI-001, is a CAR‐engineered allogeneic γδ T cell therapy directed against CD20 for the treatment of relapsed or refractory B-cell malignancies.